Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises D. Carnegie & Co in connection with Blackstone’s mandatory offer
Mandate

Vinge advises D. Carnegie & Co in connection with Blackstone’s mandatory offer

October 27, 2016

Vinge has advised D. Carnegie & Co AB (publ) (“D. Carnegie & Co”) in connection with a mandatory offer to the shareholders and warrant holders of D. Carnegie & Co, made by Blackstone through Vega Holdco S.à r.l. (”Vega Holdco”). Vega Holdco offers SEK 100 in cash per A- and B-share in D. Carnegie & Co. Based on all outstanding shares and warrants in the company, the total value of D. Carnegie & Co amounts to approximately SEK 7.8 billion.

Vinge’s team primarily consisted of Jesper Schönbeck, David Andersson and Sofie Bjärtun.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026